Navigating the future of cell therapies with bit.bio exec Kathryn Corzo

Kathryn Corzo is currently the president and chief operating officer of bit.bio. The Cambridge, UK–based synthetic biology company specializes in providing human cells for research, drug discovery and cell therapy.

Her previous roles include a stint as the head of development for oncology cell therapies at Takeda. She also led the North American Innovation Center and R&D Digital Accelerator at Sanofi and held a leadership role in Lilly’s oncology business unit.

Bit.bio’s differentiated approach

Corzo’s decision to join bit.bio was rooted in the company’s pioneering approach to cell therapy. “Joining bit.bio became a clear choice,” she recalls. “The platform technology at bit.bio offers a solution to some of the significant challenges in the cell therapy field, mainly by manufacturing consistent cells at scale, speed and reduced costs thus democratizing access to human cells.…

Read more
  • August 28, 2023
  • 0

100 top cell and gene therapy companies to watch in 2023

[Image courtesy of ipopba/Adobe Stock]

The cell and gene therapy sector is poised to deliver a wave of new therapies that could potentially cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023.

While manufacturing and regulatory challenges remain, the cell and gene therapy industry continues to offer significant therapeutic potential and commercial opportunities.

This year, we have beefed up our list of leading cell and gene therapy companies, doubling the number of organizations from 50 to 100.

In selecting the companies for this list, we weighed public companies’ degree of involvement in cell and gene therapy, including drug developers, equipment vendors and CDMOs specializing in the area. For private companies, we factored in their funding levels, pipeline and degree of history for the list.

B…

Read more
  • March 10, 2023
  • 0